An overview of early investigational therapies for chemoresistant ovarian cancer.

An overview of early investigational therapies for chemoresistant ovarian cancer.

Item
http://www.wikidata.org/entity/Q38553247
New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genesRole of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer.Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.The clinicopathological parameters significance of CD133 and Nestin in epithelial ovarian cancer: a meta-analysis.Targeting estrogen receptor beta (ERβ) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERβ expression and functionality.Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer
P2860

An overview of early investigational therapies for chemoresistant ovarian cancer.

Item
http://www.wikidata.org/entity/Q38553247
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
An overview of early investigational therapies for chemoresistant ovarian cancer.
@en
type
label
An overview of early investigational therapies for chemoresistant ovarian cancer.
@en
prefLabel
An overview of early investigational therapies for chemoresistant ovarian cancer.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
An overview of early investigational therapies for chemoresistant ovarian cancer
@en
P2093
P2860
P304
P31
P356
10.1517/13543784.2015.1072168
P407
P433
P478
P50
P577
P698
P921